Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.
Matsukawa A, Rajwa P, Kawada T, Bekku K, Laukhtina E, Klemm J, Pradere B, Mori K, Karakiewicz PI, Kimura T, Chlosta P, Shariat SF, Yanagisawa T. Matsukawa A, et al. Among authors: kimura t. Int J Clin Oncol. 2024 Apr 6. doi: 10.1007/s10147-024-02485-4. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38582807 Review.
Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancer.
Miyajima K, Suzuki H, Urabe F, Iwatani K, Imai Y, Yasue K, Yanagisawa T, Kimura S, Tashiro K, Tsuzuki S, Koike Y, Miki J, Yuen S, Sasaki T, Aoki M, Sato S, Takahashi H, Miki K, Kimura T. Miyajima K, et al. Among authors: kimura s, kimura t. Int J Clin Oncol. 2023 Sep;28(9):1200-1206. doi: 10.1007/s10147-023-02383-1. Epub 2023 Jul 11. Int J Clin Oncol. 2023. PMID: 37432614
Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective study.
Takahashi K, Urabe F, Suhara Y, Nakano J, Yoshihara K, Goto Y, Sadakane I, Koike Y, Yata Y, Suzuki H, Kurawaki S, Miyajima K, Iwatani K, Imai Y, Sakanaka K, Nakazono M, Kurauchi T, Kayano S, Onuma H, Aikawa K, Yanagisawa T, Tashiro K, Tsuzuki S, Koike Y, Furuta A, Miki J, Kimura T. Takahashi K, et al. Among authors: kimura t. Jpn J Clin Oncol. 2023 Dec 7;53(12):1208-1214. doi: 10.1093/jjco/hyad118. Jpn J Clin Oncol. 2023. PMID: 37647644
Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer.
Yanagisawa T, Sato S, Hayashida Y, Okada Y, Fukuokaya W, Iwatani K, Matsukawa A, Shimoda M, Takahashi H, Kimura T, Shariat SF, Miki J. Yanagisawa T, et al. Among authors: kimura t. Urol Oncol. 2023 Dec;41(12):484.e7-484.e15. doi: 10.1016/j.urolonc.2023.08.004. Epub 2023 Sep 14. Urol Oncol. 2023. PMID: 37714725
Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study.
Kagawa H, Urabe F, Kiuchi Y, Katsumi K, Yamaguchi R, Suhara Y, Yoshihara K, Goto Y, Sadakane I, Yata Y, Saito S, Kurawaki S, Ajisaka S, Miyajima K, Takahashi K, Iwatani K, Imai Y, Sakanaka K, Nakazono M, Kurauchi T, Kayano S, Onuma H, Aikawa K, Yanagisawa T, Tashiro K, Tsuzuki S, Furuta A, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Kagawa H, et al. Among authors: kimura t. Int J Clin Oncol. 2024 Jan;29(1):55-63. doi: 10.1007/s10147-023-02424-9. Epub 2023 Oct 21. Int J Clin Oncol. 2024. PMID: 37863996
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.
Nukaya T, Takahara K, Yoshizawa A, Saruta M, Yano Y, Ohno T, Uchimoto T, Fukuokaya W, Adachi T, Yamazaki S, Tokushige S, Nishimura K, Tsujino T, Nakamori K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Hirasawa Y, Hashimoto T, Komura K, Inamoto T, Miki J, Kimura T, Ohno Y, Azuma H, Shiroki R. Nukaya T, et al. Among authors: kimura t. Clin Genitourin Cancer. 2024 Feb;22(1):76-83. doi: 10.1016/j.clgc.2023.09.007. Epub 2023 Oct 1. Clin Genitourin Cancer. 2024. PMID: 37880020
Clinical Significance of Intraductal Carcinoma of the Prostate After High-Dose Brachytherapy With External Beam Radiation Therapy: A Single Institution Series and an Updated Meta-Analysis.
Miyajima K, Sato S, Uchida N, Suzuki H, Iwatani K, Imai Y, Aikawa K, Yanagisawa T, Kimura S, Tashiro K, Tsuzuki S, Honda M, Koike Y, Miki J, Miki K, Shimomura T, Yuen S, Yamada Y, Aoki M, Takahashi H, Urabe F, Kimura T. Miyajima K, et al. Among authors: kimura s, kimura t. Clin Genitourin Cancer. 2024 Apr;22(2):149-156.e1. doi: 10.1016/j.clgc.2023.10.005. Epub 2023 Oct 25. Clin Genitourin Cancer. 2024. PMID: 38007354
Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis.
Shimomura T, Mori K, Yasue K, Matsukawa A, Fukuokaya W, Yanagisawa T, Hata K, Murakami M, Koike Y, Miki J, Yamada H, Kimura T. Shimomura T, et al. Among authors: kimura t. Int J Clin Oncol. 2024 Feb;29(2):213-221. doi: 10.1007/s10147-023-02441-8. Epub 2023 Dec 16. Int J Clin Oncol. 2024. PMID: 38103156
10,158 results
You have reached the last available page of results. Please see the User Guide for more information.